The World Alzheimer's Disease Market (Incidence, Treatments, Key Companies, Pipeline and Trends)

TABLE OF CONTENTS

CHAPTER ONE: EXECUTIVE SUMMARY

• Background
• Scope and Methodology
• Size and Growth of the Market
• Key Issues and Trends Affecting Market
• Leading Competitors

CHAPTER TWO: INTRODUCTION

• Overview
• Structural Organization of the Neurological System
  • Central Nervous System
  • The Brain
• Aging and Alzheimer’s Disease
• Stages of Alzheimer’s Disease
• Risk Factors
• Life Expectancy and the Growing Incidence of Alzheimer’s Disease
• World Demographics
• Prevalence, Incidence and Mortality
• Insurance for the Elderly in the United States
• Generic Competition
  • Teva/Mutual Pharmaceutical/United Research Laboratories and Eisai
  • Dr. Reddy’s and Novartis
  • Ranbaxy and Ortho-McNeil Neurologics

CHAPTER THREE: ALZHEIMER’S DISEASE PRODUCT ANALYSIS

• Overview of Products
• Aricept
• Namenda/Exiba/Axura
• Exelon
• Razadyne
• Other Products

CHAPTER FOUR: RESEARCH AND DEVELOPMENT

• Overview
• Phase III
  • AAB-001
  • Aricept SR
  • Exelon Transdermal Patch (ONO 2540)
  • Flurizan
  • LY450139
  • Memryte
  • Namenda Once-Daily
  • Rosiglitazone XR
  • Xaliproden
  Phase II
  • Dimebon
  • AC-1202
  • Ispronicline
  • MEM-3454
  • MEM-1003
  • AN-1792
  • ABT-089
  • ACC-001 and QS-21
  • AL-108
  • CX717
  • ELND-005
  • Huperzine A
  • Immune globulin, intravenous
  • LY2062430
  • Lecozotan SR
  • MK-0249
  • MK-0952
  • Neramenxane
  • NIC5-15
  • PRX-03140
  • Rasagiline mesylate
  • SAM-531
  • SGS742
  • T 817 MA
  • TTP 488
  Phase I
  • 933776
  • Aricept Transdermal Patch
  • AV 965
  • AVE 8112
  • Bapineuzumab
  • CAD-106
  • CERE-110
  • CTS-21166
  • EVP 6124
  • GSI 953
  • Lecozotan SR
  • MEM-1414
  • NGX267
  • Oxigon
  • Paz-417
  • PF-4360365
  • PF-30804014
  • R1450
  • R4996/MEM 63908
  • SSR 180711
  • V 950
  Preclinical Development
  • TTP 4000
  • AAB-002
  • Alzhemed
  • BACE Inhibitors (TTP 854)
  • CX1739
  • E2012
  • Gamma-secretase inhibitor
  • GSI-136
  • MEM-1917
  • MPI-442690
  • PBT2/PBT3/PBT4
  • SAR 110894

CHAPTER FIVE: MARKET AND COMPETITOR ANALYSIS

• Market Overview
• Market Analysis by Product Type
• Market Analysis by Country
• Competitive Analysis
• Leading Products

CHAPTER SIX: LEADING MANUFACTURERS

• Overview
• Eisai Co., Ltd.
• Forest Laboratories
• H. Lundbeck A/S
• Johnson & Johnson
• Merz Pharma GmbH
• Novartis AG
• Pfizer, Inc.

APPENDIX: LIST OF MAJOR COMPANIES LIST OF EXHIBITS CHAPTER ONE: EXECUTIVE SUMMARY

• Figure 1-1: Alzheimer’s Disease Market Analysis: 2005-2012

CHAPTER TWO: INTRODUCTION

• Table 2-1: Alzheimer’s Disease Stages 1-7 and Descriptions
• Table 2-2: Average Life Expectancy in Years by Country 1980, 2004 and 2006
• Figure 2-1: Average Life Expectancy in Years by Country 1980, 2004 and 2006
• Table 2-3: World Population by Selected Geographical Region, 2007 - 2050
• Figure 2-2: World Population by Selected Geographical Region, 2007-2050
• Table 2-4: Estimated World Population by Age and Geographical Region, 2007
• Figure 2-3: Estimated World Population by Age and Geographical Region, 2007
• Table 2-5: Percent Population Over 65 by Year and Region
• Figure 2-4: Estimated World Population by Age, 2007 and 2050
• Table 2-6: Estimated Prevalence, Incidence and Mortality for Alzheimer’s Disease* by Region/Country, 2007
• Figure 2-5: Estimated World Prevalence and Incidence of Alzheimer’s Diseases by Region, 2007
• Figure 2-6: World Prevalence of Alzheimer’s Disease Compared to Rest of Population Over Age 65, 2007
• Table 2-7: Health Insurance Trends in the United States, Estimated 2007 (millions)

CHAPTER THREE: ALZHEIMER’S DISEASE PRODUCT ANALYSIS

• Table 3-1: Comparison of Marketed Alzheimer’s Disease Treatments
• Figure 3-1: Alzheimer Product Sales Analysis, 2005-2007
• Figure 3-2: Aricept Sales Analysis, 2005-2007
• Figure 3-3: Namenda/Exiba/Axura Sales Analysis, 2005-2007
• Figure 3-4: Exelon Sales Analysis, 2005-2007
• Figure 3-5: Razadyne Sales Analysis, 2005-2007

CHAPTER FOUR: RESEARCH AND DEVELOPMENT

• Figure 4-1: Alzheimer’s Disease Treatments in Development, 2005, 2006, and 2007
• Table 4-1: Alzheimer’s Disease Therapies in Development

CHAPTER FIVE: MARKET AND COMPETITOR ANALYSIS

• Table 5-1: Alzheimer’s Disease Market Analysis, 2005-2007
• Table 5-2: Forecasted Alzheimer’s Disease Market Analysis: 2008-2012
• Figure 5-1: Alzheimer’s Disease Market Analysis: 2005-2012
• Table 5-3: Alzheimer’s Disease Market Analysis by Drug Type, (Cholinesterase inhibitors, NMDA antagonists), 2005-2007
• Figure 5-2: Alzheimer’s Disease Market Analysis by Drug Type, (Cholinesterase inhibitors, NMDA antagonists), 2005-2007
• Figure 5-3: Alzheimer’s Disease Market Share by Drug Type, (Cholinesterase inhibitors, NMDA antagonists), 2005 Figure 5-4: Alzheimer’s Disease Market Share by Drug Type, (Cholinesterase inhibitors, NMDA antagonists), 2007
• Table 5-4: Alzheimer’s Disease Market Analysis by Region/Country, 2007
• Figure 5-5: Alzheimer’s Disease Market Analysis by Region/Country, 2007
• Table 5-5: Alzheimer’s Disease Market Estimated Revenues and Market Share of Leading Suppliers 2007
• Figure 5-6: Alzheimer’s Disease Market Estimated Market Share by Leading Suppliers 2007
• Table 5-6: Alzheimer’s Disease Market Estimated Sales of Top Products 2007
• Figure 5-7 : Alzheimer’s Disease Market Estimated Market Share of Top Products, 2007

CHAPTER SIX: LEADING MANUFACTURERS

• Figure 6-1: Eisai’s Net Revenues and R&D Expenses for 2006 and 2007
• Figure 6-2: Forest’s Net Revenues and R&D Expenses for 2006 and 2007
• Figure 6-3: Lundbeck’s Net Revenues and R&D Expenses for 2006 and 2007
• Figure 6-4: Johnson & Johnson’s Net Revenues and R&D Expenses for 2006 and 2007
• Figure 6-5: Merz Pharma’s Net Revenues and R&D Expenses for 2006 and 2007
• Figure 6-6: Novartis’ Net Revenues and R&D Expenses for 2006 and 2007
• Figure 6-7: Pfizer’s Net Revenues and R&D Expenses for 2006 and 2007